Clinical trial results show low-intensity therapy can achieve positive outcomes for certain paediatric leukaemia subtypes
Jude Children’s Research Hospital, USA, demonstrates benefits to using genomics and early treatment response to…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Risk model identifies advanced cancer trial patients at highest risk for acute care use
Investigators from the SWOG Cancer Research Network have developed and validated a risk prediction model…
Study confirms fibrosis as a prognostic indicator in the most common breast cancer, and opens the way to antifibrotic drug treatments
The most common breast cancer is HER2-negative, so called because it has low amounts of…
New cancer cachexia treatment boosts weight gain and patient activity
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from…
New prostate biopsy technique lowers infection risk
A multi-institutional clinical trial led by Weill Cornell Medicine and New York-Presbyterian investigators showed that…
Black patients with triple-negative breast cancer may be less likely to receive immunotherapy than white patients
In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower…
Combination treatment improves response to immunotherapy for lung cancer
Researchers at the Francis Crick Institute, UK, in collaboration with Revolution Medicines, have tested a…
Do cancer and cancer-related treatments increase cardiovascular disease risk in older cancer survivors?
A study based on clinical trial data found higher risks of stroke, heart attack, and…
Nearly 200 potential mammary carcinogens found in food contact materials
Researchers from the Food Packaging Forum identify and discuss nearly 200 potential breast carcinogens that…
ENZAMET: Advanced prostate cancer poor outcomes can be reversed with targeted treatment
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New…